Drugs

, Volume 72, Issue 1, pp 35–48 | Cite as

Seasonal Influenza Vaccination of Healthy Working-Age Adults

A Review of Economic Evaluations
  • Justin Gatwood
  • Martin I. Meltzer
  • Mark Messonnier
  • Ismael R. Ortega-Sanchez
  • Rajesh Balkrishnan
  • Lisa A. Prosser
Review Article

Abstract

The recent impact of influenza on the working-age population of the US has led to changes in the recommendations for vaccination against seasonal influenza; however, the implications of vaccinating such a population have been debated. A review of cost-effectiveness analyses of vaccinating the working-age population of the US against seasonal influenza was conducted using articles published between January 1990 and January 2010. Studies considered for inclusion were identified using MEDLINE, EMBASE and Econlit. Reviewers worked in pairs, and each team member independently extracted relevant data using a standard abstraction form. The source and appropriateness of parameters (epidemiological data, probabilities and costs), the designs employed and the sufficiency of sensitivity analysis were considered during review. Key inputs extracted from the selected studies included influenza or influenza-like illness attack rates, outpatient visits averted, total vaccination days and lost workdays.

Seven studies were identified as appropriate for this review. All studies were conducted in the US and from the societal perspective; three were randomized controlled trials and the remaining four were economic simulation models comparing vaccination and influenza antiviral drugs or no intervention; analyses focused on healthy working-age adults aged 18–49 years. Results ranged from net savings of $US68.96 to net costs of $US85.92 per person vaccinated (four studies) and net costs of $US 104-1005 per episode of influenza averted (one study). Only two studies reported cost-effectiveness ratios; these ranged from $US26 565 to $US50 512 per quality-adjusted life-year gained. Nearly all of the studies conducted sensitivity analysis; results were most sensitive to variation in wage rates, levels of worker productivity, the costs and effectiveness of vaccination, and the rate of influenza illness. Review of the included studies suggests that seasonal influenza vaccination of healthy, working-age adults is generally not cost saving, requiring an investment to generate health benefits. The decision to vaccinate such a group will depend upon the societal and payer valuation of those benefits.

References

  1. 1.
    Kuehn BM. CDC Advisory committee recommends nearly universal influenza vaccination. JAMA 2010; 303(12): 1136PubMedCrossRefGoogle Scholar
  2. 2.
    Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 [published erratum appears in MMWR Recomm Rep 2009 Aug 21; 58(32): 896–7]. MMWR Recomm Rep 2009 Jul 31; 58 (RR-8): 1–52Google Scholar
  3. 3.
    Bridges CB, Winquist AG, Fukuda K, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49 (RR-3): 1–38Google Scholar
  4. 4.
    Drummond MF, O’Brien BJ, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997Google Scholar
  5. 5.
    US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. 2010 [online]. Available from URL: http://www.bls.gov/cpi/#tables [Accessed 2010 Aug 5]
  6. 6.
    Molinari NAM, Ortega-Sanchez IR, Messonnier ML, et al. The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007; 25: 5086–96PubMedCrossRefGoogle Scholar
  7. 7.
    Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995; 333(14): 889–93PubMedCrossRefGoogle Scholar
  8. 8.
    Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: a randomized controlled trial. JAMA 2000; 284(13): 1655–63PubMedCrossRefGoogle Scholar
  9. 9.
    Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 2003; 21: 2207–17PubMedCrossRefGoogle Scholar
  10. 10.
    Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med 2001; 161: 749–59PubMedCrossRefGoogle Scholar
  11. 11.
    Lee PY, Matchar DB, Clements DA, et al. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Ann Intern Med 2002; 137: 225–31PubMedCrossRefGoogle Scholar
  12. 12.
    Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005; 118:68–77PubMedCrossRefGoogle Scholar
  13. 13.
    Prosser LA, O’Brien MA, Molinari NAM, et al. Non-traditional settings for influenza vaccination of adults. Pharmacoeconomics 2008; 26(2): 163–78PubMedCrossRefGoogle Scholar
  14. 14.
    Hammond ML, Ferris AA, Faine S, et al. Effective protection against influenza after vaccination with subunit vaccine. Med J Aust 1978; 1: 301–3PubMedGoogle Scholar
  15. 15.
    Keech M, Scott AJ, Ryan PJ. The impact of influenza an influenza-like illness on productivity and healthcare resource utilization in a working population. Occup Med (Lond) 1998; 48: 85–90CrossRefGoogle Scholar
  16. 16.
    Savidan E, Chevat C, Marsh G. Economic evidence of influenza vaccination in children. Health Policy 2008; 86: 142–52PubMedCrossRefGoogle Scholar
  17. 17.
    Fiore AE, Fry A, Shay D, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60(RR01): 1–24PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • Justin Gatwood
    • 1
  • Martin I. Meltzer
    • 2
  • Mark Messonnier
    • 2
  • Ismael R. Ortega-Sanchez
    • 2
  • Rajesh Balkrishnan
    • 1
  • Lisa A. Prosser
    • 3
  1. 1.University of Michigan College of PharmacyAnn ArborUSA
  2. 2.Centers for Disease Control and PreventionAtlantaUSA
  3. 3.University of Michigan Medical SchoolAnn ArborUSA

Personalised recommendations